Provided by Tiger Fintech (Singapore) Pte. Ltd.

Omega Therapeutics

0.1426
+0.0000
Volume:- -
Turnover:- -
Market Cap:7.90M
PE:-0.11
High:0.1426
Open:0.1426
Low:0.1426
Close:0.1426
Loading ...

Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform

MT Newswires Live
·
15 Nov 2024

Piper Sandler Remains a Buy on Omega Therapeutics (OMGA)

TIPRANKS
·
15 Nov 2024

Omega Therapeutics price target lowered to $4 from $9 at Piper Sandler

TIPRANKS
·
15 Nov 2024

U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart

Reuters
·
15 Nov 2024

Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
15 Nov 2024

Omega Therapeutics Names Kaan Certel as CEO

Dow Jones
·
15 Nov 2024

Omega Therapeutics provides updated MYCHELANGELO I data

TIPRANKS
·
15 Nov 2024

Omega Therapeutics CEO Mahesh Karande to depart, Kaan Certel to succeed

TIPRANKS
·
15 Nov 2024

Omega Therapeutics reports Q3 revenue $2.61M, consensus $1.34M

TIPRANKS
·
15 Nov 2024

Omega Therapeutics Q3 2024 GAAP EPS $(0.30) Misses $(0.28) Estimate, Sales $2.612M Beat $1.240M Estimate

Benzinga
·
15 Nov 2024

Omega Therapeutics Inc - Collaboration With Novo Nordisk for Development of an Epigenomic Controller for Obesity Continues to Advance

THOMSON REUTERS
·
15 Nov 2024

Omega Therapeutics Inc - Appoints Kaan Certel as CEO

THOMSON REUTERS
·
15 Nov 2024

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

THOMSON REUTERS
·
15 Nov 2024

Omega Therapeutics Inc - Pursuing Strategic Partnership Opportunities to Support Development of New and Existing Pipeline Programs

THOMSON REUTERS
·
15 Nov 2024

Omega Therapeutics Inc - Otx-2002 Shows Favorable Safety Profile in Phase 1 Trial

THOMSON REUTERS
·
15 Nov 2024

Omega Therapeutics Inc - Exploring Partnerships for Phase 2 Development of Otx-2002

THOMSON REUTERS
·
15 Nov 2024

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

GlobeNewswire
·
15 Nov 2024

Omega Pacific Welcomes Expert to Boost Growth

TIPRANKS
·
13 Nov 2024

Omega Pacific Gains 51% Interest in Williams Property

TIPRANKS
·
13 Nov 2024

Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last?

Zacks
·
29 Oct 2024